Absorb BRS for in-stent restenosis: the final bow before (scaffold) collapse?
作者信息
Arroyo Diego, Cook Stéphane
机构信息
Cardiology, University and Hospital Fribourg, Fribourg, Switzerland
Cardiology, University and Hospital Fribourg, Fribourg, Switzerland.
出版信息
Open Heart. 2021 Oct;8(2). doi: 10.1136/openhrt-2021-001838.
Abstract
摘要
相似文献
1
Absorb BRS for in-stent restenosis: the final bow before (scaffold) collapse?
Open Heart. 2021 Oct;8(2). doi: 10.1136/openhrt-2021-001838.
2
Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
JACC Cardiovasc Interv. 2017 Sep 25;10(18):1867-1877. doi: 10.1016/j.jcin.2017.07.035.
3
Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
EuroIntervention. 2017 Dec 20;13(11):1303-1310. doi: 10.4244/EIJ-D-17-00458.
4
Treatment of In-Stent Restenosis: When the Stent Is No Longer There.
JACC Cardiovasc Interv. 2020 Apr 13;13(7):e53-e55. doi: 10.1016/j.jcin.2019.10.032. Epub 2019 Dec 25.
5
Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.
Cardiovasc Revasc Med. 2019 Jul;20(7):577-582. doi: 10.1016/j.carrev.2019.04.013. Epub 2019 Apr 16.
6
Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Catheter Cardiovasc Interv. 2016 Apr;87(5):822-9. doi: 10.1002/ccd.26346. Epub 2015 Dec 28.
7
Edge vascular response after percutaneous coronary intervention: an intracoronary ultrasound and optical coherence tomography appraisal: from radioactive platforms to first- and second-generation drug-eluting stents and bioresorbable scaffolds.
JACC Cardiovasc Interv. 2013 Mar;6(3):211-21. doi: 10.1016/j.jcin.2013.01.132.
8
Late stent thrombosis after the use of a bioresorbable vascular scaffold for the treatment of in-stent restenosis.
Coron Artery Dis. 2016 Dec;27(8):709-710. doi: 10.1097/MCA.0000000000000405.
9
First-in-man demonstration of complete bioresorbable vascular scaffold resorption after treatment of in-stent restenosis.
Coron Artery Dis. 2017 Aug;28(5):437-439. doi: 10.1097/MCA.0000000000000505.
10
Challenging treatment of in-stent restenosis in a coronary bifurcation by implantation of a bioresorbable scaffold under optical coherence tomography guidance.
Cardiol J. 2019;26(3):304-306. doi: 10.5603/CJ.2019.0063.
本文引用的文献
1
Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.
Open Heart. 2021 Sep;8(2). doi: 10.1136/openhrt-2021-001776.
2
Five-year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
Catheter Cardiovasc Interv. 2022 Feb;99(3):523-532. doi: 10.1002/ccd.29837. Epub 2021 Jun 26.
3
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial.
EuroIntervention. 2020 Oct 23;16(8):645-653. doi: 10.4244/EIJ-D-19-01079.
4
Long-Term Outcomes of Absorb Bioresorbable Vascular Scaffold vs. Everolimus-Eluting Metallic Stent - A Randomized Comparison Through 5 Years in Japan.
Circ J. 2020 Apr 24;84(5):733-741. doi: 10.1253/circj.CJ-19-1184. Epub 2020 Mar 26.
5
Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.
Circulation. 2019 Dec 3;140(23):1895-1903. doi: 10.1161/CIRCULATIONAHA.119.042584. Epub 2019 Sep 25.
6
Three to four years outcomes of the absorb bioresorbable vascular scaffold versus second-generation drug-eluting stent: A meta-analysis.
Catheter Cardiovasc Interv. 2020 Feb;95(2):216-223. doi: 10.1002/ccd.28290. Epub 2019 Apr 19.
7
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Lancet. 2018 Oct 27;392(10157):1530-1540. doi: 10.1016/S0140-6736(18)32283-9. Epub 2018 Sep 25.
8
Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
Circulation. 2018 Jan 30;137(5):464-479. doi: 10.1161/CIRCULATIONAHA.117.031843. Epub 2017 Oct 31.
9
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30.
10
Ten-year clinical outcomes after sirolimus-eluting stent implantation: Impact of an in-stent restenosis target lesion.
Am Heart J. 2016 May;175:47-55. doi: 10.1016/j.ahj.2016.02.005. Epub 2016 Feb 17.
Zotero 插件